Abstract
Omega-3 fatty acid (n-3 FA) consumption has been linked to reductions in the risk of death from coronary heart disease and, recently, to lower heart rates (HRs). The investigators previously observed a reduction of 5 beats/min in HR in patients with coronary heart disease given n-3 FAs (eicosapentaenoic acid and docosahexaenoic acid) for 4 months. Reductions in HR may be explained by enhanced vagal tone, influences on cardiac voltage-gated ion channels, or both. The hypothesis that n-3 FAs would affect HR independent of vagal input was investigated by studying the effects of n-3 FA supplementation on HR in patients with denervated hearts after orthotopic heart transplantation. Electrocardiographic data obtained in 2 prospective trials in which 18 heart transplant recipients received n-3 FA supplementation (1 to 3.4 g/day) for 4 to 6 months were collected. Patients were studied 4.4 ± 2.6 years after transplantation. HR, QRS complex, and QTc duration were determined before and after treatment. Pretreatment HR was reduced from 88 ± 14 to 83 ± 13 beats/min after n-3 FA treatment (p = 0.016). QRS duration increased from 107 ± 24 to 117 ± 25 ms (p = 0.001). QTc duration remained unchanged from baseline (427 ± 34 ms) to study end (424 ± 39 ms). In conclusion, n-3 FA supplementation reduced HR and prolonged QRS duration in heart transplant recipients who were presumably devoid of vagal innervation. These findings suggest that n-3 FAs may modify electrophysiologic properties of the myocardium itself.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1393-1395 |
| Number of pages | 3 |
| Journal | American Journal of Cardiology |
| Volume | 98 |
| Issue number | 10 |
| DOIs | |
| State | Published - Nov 15 2006 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Effects of Omega-3 Fatty Acids on Heart Rate in Cardiac Transplant Recipients††Disclaimer : Saint Luke's Hospital holds a minority interest in OmegaMetrix, LLC, Kansas City, Missouri, a company offering blood omega-3 fatty acid testing. / Harris, William; Gonzales, Michael; Laney, Nathan; Sastre, Antonio; Borkon, A. Michael.
In: American Journal of Cardiology, Vol. 98, No. 10, 15.11.2006, p. 1393-1395.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of Omega-3 Fatty Acids on Heart Rate in Cardiac Transplant Recipients††Disclaimer
T2 - Saint Luke's Hospital holds a minority interest in OmegaMetrix, LLC, Kansas City, Missouri, a company offering blood omega-3 fatty acid testing.
AU - Harris, William
AU - Gonzales, Michael
AU - Laney, Nathan
AU - Sastre, Antonio
AU - Borkon, A. Michael
PY - 2006/11/15
Y1 - 2006/11/15
N2 - Omega-3 fatty acid (n-3 FA) consumption has been linked to reductions in the risk of death from coronary heart disease and, recently, to lower heart rates (HRs). The investigators previously observed a reduction of 5 beats/min in HR in patients with coronary heart disease given n-3 FAs (eicosapentaenoic acid and docosahexaenoic acid) for 4 months. Reductions in HR may be explained by enhanced vagal tone, influences on cardiac voltage-gated ion channels, or both. The hypothesis that n-3 FAs would affect HR independent of vagal input was investigated by studying the effects of n-3 FA supplementation on HR in patients with denervated hearts after orthotopic heart transplantation. Electrocardiographic data obtained in 2 prospective trials in which 18 heart transplant recipients received n-3 FA supplementation (1 to 3.4 g/day) for 4 to 6 months were collected. Patients were studied 4.4 ± 2.6 years after transplantation. HR, QRS complex, and QTc duration were determined before and after treatment. Pretreatment HR was reduced from 88 ± 14 to 83 ± 13 beats/min after n-3 FA treatment (p = 0.016). QRS duration increased from 107 ± 24 to 117 ± 25 ms (p = 0.001). QTc duration remained unchanged from baseline (427 ± 34 ms) to study end (424 ± 39 ms). In conclusion, n-3 FA supplementation reduced HR and prolonged QRS duration in heart transplant recipients who were presumably devoid of vagal innervation. These findings suggest that n-3 FAs may modify electrophysiologic properties of the myocardium itself.
AB - Omega-3 fatty acid (n-3 FA) consumption has been linked to reductions in the risk of death from coronary heart disease and, recently, to lower heart rates (HRs). The investigators previously observed a reduction of 5 beats/min in HR in patients with coronary heart disease given n-3 FAs (eicosapentaenoic acid and docosahexaenoic acid) for 4 months. Reductions in HR may be explained by enhanced vagal tone, influences on cardiac voltage-gated ion channels, or both. The hypothesis that n-3 FAs would affect HR independent of vagal input was investigated by studying the effects of n-3 FA supplementation on HR in patients with denervated hearts after orthotopic heart transplantation. Electrocardiographic data obtained in 2 prospective trials in which 18 heart transplant recipients received n-3 FA supplementation (1 to 3.4 g/day) for 4 to 6 months were collected. Patients were studied 4.4 ± 2.6 years after transplantation. HR, QRS complex, and QTc duration were determined before and after treatment. Pretreatment HR was reduced from 88 ± 14 to 83 ± 13 beats/min after n-3 FA treatment (p = 0.016). QRS duration increased from 107 ± 24 to 117 ± 25 ms (p = 0.001). QTc duration remained unchanged from baseline (427 ± 34 ms) to study end (424 ± 39 ms). In conclusion, n-3 FA supplementation reduced HR and prolonged QRS duration in heart transplant recipients who were presumably devoid of vagal innervation. These findings suggest that n-3 FAs may modify electrophysiologic properties of the myocardium itself.
UR - http://www.scopus.com/inward/record.url?scp=33750521789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750521789&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2006.06.033
DO - 10.1016/j.amjcard.2006.06.033
M3 - Article
C2 - 17134636
AN - SCOPUS:33750521789
VL - 98
SP - 1393
EP - 1395
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 10
ER -